Skip to search formSkip to main contentSkip to account menu

FBS0701

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
FBS0701: un nuovo chelante orale nel trattamento del paziente con sovraccarico trasfusionale di ferro
Background There is still a clinical need for a well-tolerated and safe iron chelator for the treatment of transfusional iron… 
2012
2012
FBS0701, a novel oral iron chelator, in transfusional iron overload A phase 2 study of the safety, tolerability and pharmacodynamics of
Abstract This was a 24-week, multicenter Phase-2 study designed to assess safety, tolerability, and pharmacodynamics of FBS0701… 
2011
2011
Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study
Abstract 690 [][1] BACKGROUND: The iron chelators in current clinical use - deferoxamine, deferasirox, deferiprone - are useful… 
2010
2010
Single oral dose cure of lethal P. yoelii with a new iron chelator in human clinical trials for iron overload
Background Iron chelators for the treatment of malaria have proven therapeutic activity in vitro and in vivo in both humans and… 
2010
2010
A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload
Abstract 2057 Background: Iron chelators in current use (parenteral deferoxamine, oral deferasirox and deferiprone) are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)